Patent · US Active

Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof

US9120853B2 · kind B2 · utility

39Cited by

10References

43Claims

0Family size

Assignee

CytomX Therapeutics, Inc. · US

Inventors

Henry B. Lowman · El Granada, US
Luc Desnoyers · San Francisco, US
Shouchun Liu · Burlingame, US
James William West · Lompoc, US
Jason Gary Sagert · Lompoc, US
Olga Vasiljeva · Cupertino, US
Elizabeth-Edna Mary Menendez · San Mateo, US

Key dates

Filing date	Apr 26, 2013
Grant date	Sep 1, 2015
Priority date	—
Expiry date	Apr 26, 2033

Classification

Technology area (CPC G)Physics
CPC primaryG01N2333/71
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention relates generally to activatable antibodies that include a masking moiety (MM), a cleavable moiety (CM), and an antibody (AB) that specifically binds to epidermal growth factor receptor (EGFR), and to methods of making and using these anti-EGFR activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.